Coagulases as determinants of protective immune responses against Staphylococcus aureus

Infection and Immunity

Volumn 80, Issue 10, 2012, Pages 3389-3398

  McAdow, Molly ^a   DeDent, Andrea C ^a   Emolo, Carla ^a   Cheng, Alice G ^a   Kreiswirth, Barry N ^b   Missiakas, Dominique M ^a   Schneewinda, Olaf ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COAGULASE; COENZYME A; HYBRID PROTEIN; PROTHROMBIN; PROTHROMBIN ANTIBODY; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; FEMALE; GENE SEQUENCE; IMMUNE RESPONSE; IMMUNITY; MOUSE; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; BINDING SITES; COAGULASE; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOME, BACTERIAL; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 84867596118     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00562-12     Document Type: Article

References (45)

1. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes. J. Bacteriol. 190:300 -310.
2. Bjerketorp J, Jacobsson K, Frykberg L. 2004. The von Willebrand factorbinding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol. Lett. 234:309 -314.
3. Bjerketorp J, et al. 2002. A novel von Willebrand factor binding protein expressed by Staphylococcus aureus. Microbiology 148:2037-2044.
4. Boake WC. 1956. Antistaphylocoagulase in experimental staphylococcal infections. J. Immunol. 76:89 -96.
5. Cheng AG, DeDent AC, Schneewind O, Missiakas DM. 2011. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol. 19: 225-232.
6. Cheng AG, et al. 2010. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 6:e1001036. doi: 10.1371/journal.ppat.1001036.
7. DeBord KL, et al. 2006. Immunogenicity and protective immunity against bubonic and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect. Immun. 74:4910- 4914.
8. DeDent A, Kim HK, Missiakas DM, Schneewind O. 2012. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin. Immunopathol. 34:317-333.
9. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Communityassociated meticillin-resistant Staphylococcus aureus. Lancet 375:1557- 1568.
10. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase: mode of action and antigenicity. J. Gen. Microbiol. 6:95-107.
11. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008 -1015.
12. Friedrich R, et al. 2003. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425:535-539.
13. Hale JH, Smith W. 1945. The influence of coagulase on the phagocytosis of staphylococci. Br. J. Exp. Pathol. 26:209 -216.
14. Harrison KJ. 1963. Clinical trial of coagulase and alpha-hemolysin toxoids in chronic furunculosis. Br. Med. J. ii:149 -152.
15. Harrison KJ. 1964. The protection of rabbits against infection with staphylococci by immunization with staphylocoagulase toxin or toxoid. J. Pathol. Bacteriol. 87:145-150.
16. Johnstone JM, Smith DD. 1956. Coagulase activity in vivo. Nature 178: 982-983.
17. Kanemitsu K, Yamamoto H, Takemura, Kaku M, Shimada J. 2001. Relatedness between the coagulase gene 3′-end region and coagulase serotypes among Staphylococcus aureus strains. Microbiol. Immunol. 45:23-27.
18. Klevens RM, Edwards JR, Gaynes RP, and National Nosocomial Infections Surveillance System. 2008. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin. Infect. Dis. 47:927-930.
19. Klevens RM, et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
20. Koreen L, et al. 2004. spa typing method for discriminating among Staphylococcus aureus isolates: implications for use of a single marker to detect genetic micro- and macrovariation. J. Clin. Microbiol. 42:792-799.
21. Kroh HK, Panizzi P, Bock PE. 2009. von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc. Natl. Acad. Sci. U. S. A. 106:7786 -7791.
22. Lancefield R. 1962. Current knowledge of type-specific M antigens of group A streptococci. J. Immunol. 89:307-313.
23. Lancefield RC. 1928. The antigenic complex of Streptococcus hemolyticus. I. Demonstration of a type-specific substance in extracts of Streptococcus hemolyticus. J. Exp. Med. 47:91-103.
24. Lominski I. 1949. Susceptibility and resistance to staphylococcal infection. J. Gen. Microbiol. 3:IX.
25. Lominski I, Roberts GBS. 1946. A substance in uman serum inhibiting staphylocoagulase. J. Pathol. Bacteriol. 58:187-197.
26. Lominski I, et al. 1962. Immunisation against experimental staphylococcal infection with coagulase-rich preparations. Lancet i:1315-1318.
27. Lowy FD. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
28. McAdow M, et al. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 7:e1002307. doi:10.1371/journal.ppat.1002307.
29. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 10: 173. doi:10.1186/1471-2180-10-173.
30. Mora M, et al. 2005. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc. Natl. Acad. Sci. U. S. A. 102:15641-15646.
31. Much H. 1908.Ü ber eine Vorstufe des Fibrinfermentes in Kulturen von Staphylokokkus aureus. Biochem. Z. 14:143-155
32. (a)National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
33. Nuccitelli A, et al. 2011. A structure-based approach to rationally design a chimeric protein for an effective vaccine against group B Streptococcus infections. Proc. Natl. Acad. Sci. U. S. A. 108:10278 -10283.
34. Panizzi P, Friedrich R, Fuentes-Prior P, Bode W, Bock PE. 2004. The staphylocoagulase family of zymogen activator and adhesion proteins. Cell. Mol. Life Sci. 61:2793-2798.
35. Panizzi P, et al. 2006. Fibrinogen substrate recognition by staphylocoagulase (pro)thrombin complexes. J. Biol. Chem. 281:1179 -1187.
36. Panizzi P, et al. 2011. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med. 17:1142-1146.
37. Patel G, et al. 2011. Clinical and molecular epidemiology of methicillinresistant Staphylococcus aureus among patients in an ambulatory hemodialysis center. Hosp. Epidemiol. Am. 32:881- 888.
38. Rammelkamp CH, Hezebicks MM, Dingle JH. 1950. Specific coagulases of Staphylococcus aureus. J. Exp. Med. 91:295-307.
39. Rammelkamp CH, Jr, Lebovitz JJ. 1956. Immunity, epidemiology and antimicrobial resistance. The role of coagulase in staphylococcal infections. Ann. N. Y. Acad. Sci. 65:144 -151.
40. Schneewind O, Missiakas D. 2011. Structural vaccinology to thwart antigenic variation in microbial pathogens. Proc. Natl. Acad. Sci. U. S. A. 108:10029 -10030.
41. Streitfeld MM, Sallman B, Shoelson SM. 1959. Staphylocoagulase inhibition by pooled human gamma-globulin. Nature 184:1665-1666.
42. Tager M, Hales HB. 1948. The experimental production of antibodies to staphylocoagulase. J. Immunol. 60:475- 485.
43. Tenover FC, et al. 2012. Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in the United States. Antimicrob. Agents Chemother. 56:1324 -1330.
44. Watanabe S, et al. 2009. Genetic diversity of staphylocoagulase genes (coa): insight into the evolution of variable chromosomal virulence factors in Staphylococcus aureus. PLoS One 4:e5714. doi:10.1371/journal.pone.0005714.
45. Watanabe S, et al. 2005. Structural comparison of ten serotypes of staphylocoagulases in Staphylococcus aureus. J. Bacteriol. 187:3698 -3707.